According to the forecast, the European market for diabetes drugs is supposed to be the second largest diabetes drugs market globally. The CAGR of this market is expected to be 5.09% over the forecast period of 2019-2027. The growing number of individuals with diabetes and an increase in type 1 and type 2 diabetes awareness programs contributes to the market growth in this region.

EUROPE DIABETES DRUGS MARKET FORECAST 2019-2027

 Europe Diabetes Drugs Market is segmented by Diabetes Type( Type 1, Type 2) by Product Class( Insulin (Fast Acting Insulin, Intermediate Acting Insulin, Long-acting Insulin) Non-Insulin (DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors)) & by Geography

Request free sample

Report Summary

According to the forecast, the European market for diabetes drugs is supposed to be the second largest diabetes drugs market globally. The CAGR of this market is expected to be 5.09% over the forecast period of 2019-2027. The growing number of individuals with diabetes and an increase in type 1 and type 2 diabetes awareness programs contributes to the market growth in this region.

The number of diabetes cases in Europe have doubled in the last 20 years owing to the increasing obesity levels. The UK has 3 million diabetics, with England recording the maximum cases. WHO has reported that one in ten people in the UK suffer from this disease. A vast majority of diabetes patients suffer from type 2 diabetes, which is often caused by preventable factors such as a lack of physical activity, obesity or being overweight. But certain genetic factors can also increase the risk of disease, including the stress level of the mother during pregnancy and the father’s eating habits long before the pregnancy. Therefore, the growing number of individuals with diabetes and the increase in type 1 and type 2 diabetes awareness programs contribute to the market growth in this region.

The leading brands operating in the European diabetes drugs market are Eli Lilly And Company, B.Braun Melsungen Ag, Novo Nordisk A/S, Astellas Pharma, Glaxosmithkline, Macrogenics, Inc., Albireo Pharma Inc., Diavacs Inc., Pfizer, Astrazeneca Plc, Sanofi, Xoma Corp., Merck and Xeris Pharmaceuticals.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • RISING PREVALENCE OF TYPE 2 DIABETES
        • INSULIN MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • INCREASE IN PREVALENCE OF DIABETES
        • ADVANCES IN INSULIN TECHNOLOGY
        • GROWING ELDERLY POPULATION
      • MARKET RESTRAINTS
        • STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
        • LACK OF AWARENESS AMONG PEOPLE
        • COST SENSITIVITY ISSUES
      • MARKET OPPORTUNITIES
        • DEVELOPMENT OF NEW FORMULATIONS
        • INCREASING RESEARCH AND DEVELOPMENT
      • MARKET CHALLENGES
        • FIERCE MARKET COMPETITION
        • RISING CONCERNS IN SCIENTIFIC COMMUNITY
        • GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
        • POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN
    1. MARKET SEGMENTATION
      • MARKET BY DIABETES TYPE 2019-2027
        • TYPE 1
        • TYPE 2
      • MARKET BY PRODUCT CLASS 2019-2027
        • INSULIN
          • FAST ACTING INSULIN
          • INTERMEDIATE ACTING INSULIN
          • LONG-ACTING INSULIN
        • NON-INSULIN
          • DPP-4 INHIBITOR
          • GLP-1 RECEPTORS AGONISTS
          • SGLT-2 INHIBITORS
          • OTHER NON-INSULIN DRUGS
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • ETYMOLOGY OF DIABETES DRUGS MARKET
      • LEGAL, POLICY AND REGULATORY ISSUES
    2. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • THE UNITED KINGDOM
        • FRANCE
        • GERMANY
        • RUSSIA
        • ITALY
        • DENMARK
        • NORWAY
        • AUSTRIA
        • SWITZERLAND
        • SWEDEN
        • NETHERLANDS
        • REST OF EUROPE
    1. COMPANY PROFILES
      • ELI LILLY AND COMPANY
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ASTRAZENECA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BRAUN MELSUNGEN AG
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC ANALYSIS
      • NOVO NORDISK A/S
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • DIAVACS INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • XOMA CORP.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ALBIREO PHARMA INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • MACROGENICS, INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • ASTELLAS PHARMA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GLAXOSMITHKLINE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • MERCK
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • XERIS PHARMACEUTICALS
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES

    TABLE LIST

    TABLE  1 EUROPE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    TABLE  2 EUROPE DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)

    TABLE  3 EUROPE DIABETES DRUGS MARKET IN TYPE 1 DIABETES 2019-2027 ($ MILLION)

    TABLE  4 EUROPE DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 ($ MILLIONS)

    TABLE  5 EUROPE DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)

    TABLE  6 EUROPE DIABETES DRUGS MARKET IN INSULIN TYPE 2019-2027 ($ MILLION)

    TABLE  7 EUROPE DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)

    TABLE  8 EUROPE INSULIN MARKET IN FAST ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  9 EUROPE INSULIN MARKET IN INTERMEDIATE ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  10         EUROPE INSULIN MARKET IN LONG ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  11         EUROPE DIABETES DRUGS MARKET IN NON-INSULIN DRUGS 2019-2027 ($ MILLION)

    TABLE  12         EUROPE DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)

    TABLE  13         EUROPE NON-INSULIN DRUGS MARKET IN  DPP-4 INHIBITOR 2019-2027 ($ MILLION)

    TABLE  14         EUROPE NON-INSULIN DRUGS MARKET IN  GLP-1 RECEPTORS AGONISTS 2019-2027 ($ MILLION)

    TABLE  15         EUROPE NON-INSULIN DRUGS MARKET IN  SGLT-2 INHIBITORS 2019-2027 ($ MILLION)

    TABLE  16         EUROPE NON-INSULIN DRUGS MARKET IN  OTHER NON-INSULIN DRUGS 2019-2027 ($ MILLION)

    TABLE  17    EUROPE DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

     

    FIGURE LIST 

    FIGURE  1         EUROPE DIABETES DRUGS MARKET 2019-2027 ($ BILLION)

    FIGURE  2         EUROPE DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)

    FIGURE  3         AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY GENDER (IN YEARS)

    FIGURE  4         PORTER’S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET

    FIGURE  5         THE UNITED KINGDOM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  6         FRANCE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  7         GERMANY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  8         RUSSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  9         ITALY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  10       DENMARK DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  11       NORWAY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  12       AUSTRIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  13       SWITZERLAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  14       SWEDEN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  15       NETHERLANDS DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  16       REST OF EUROPE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    Segmentation

    1. MARKET SEGMENTATION
      • MARKET BY DIABETES TYPE 2019-2027
        • TYPE 1
        • TYPE 2
      • MARKET BY PRODUCT CLASS 2019-2027
        • INSULIN
          • FAST ACTING INSULIN
          • INTERMEDIATE ACTING INSULIN
          • LONG-ACTING INSULIN
        • NON-INSULIN
          • DPP-4 INHIBITOR
          • GLP-1 RECEPTORS AGONISTS
          • SGLT-2 INHIBITORS
          • OTHER NON-INSULIN DRUGS
    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • THE UNITED KINGDOM
        • FRANCE
        • GERMANY
        • RUSSIA
        • ITALY
        • DENMARK
        • NORWAY
        • AUSTRIA
        • SWITZERLAND
        • SWEDEN
        • NETHERLANDS
        • REST OF EUROPE

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS